✦ LIBER ✦

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Scribed by Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru Calin Grigorescu; Carina Hillenbach; Hrefna Kristin Johannsdottir; Barbara Klughammer; Emilio Esteban Gonzalez

Book ID: 117785904
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 381 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70385-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

88PD EFFICACY AND SAFETY OF ERLOTINIB VE

88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY

✍ Ciuleanu, T.; Stelmakh, L.; Cicenas, S.; Gonzalez, E. Esteban 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

Activity and safety of erlotinib as seco

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

✍ David Rossi; Donatella Dennetta; Marcello Ugolini; Vincenzo Catalano; Paolo Ales 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 129 KB

Erlotinib versus docetaxel as second-lin

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

✍ Garassino, Marina Chiara; Martelli, Olga; Broggini, Massimo; Farina, Gabriella; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 279 KB

A phase II study of erlotinib in combina

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

✍ Ciuleanu, T.; Tsai, C.-M.; Tsao, C.-J.; Milanowski, J.; Amoroso, D.; Heo, D.S.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 718 KB